

# Payer-Reported Unmet Need Burden Post Allogeneic Hematopoietic Cell Transplantation (HCT) Due to Poor Graft Function (PGF) and Characteristics of an Ideal Treatment for PGF

Authors, P. POTDAR, C. SENAPATI, P. NEGI  
eQuantX Pharma Analytics Solutions, Gurugram, Haryana, India

## INTRODUCTION

This research leverages a unique survey approach through the PayerPro360 platform to capture critical payer insights on genetic, regenerative, and curative therapies. Focused on understanding unmet needs and current treatment paradigms for the rare indication of poor graft function (PGF), the study aims to analyze the unmet need burden and define the characteristics of an ideal treatment for PGF. Payer research is instrumental in supporting clinical development, commercialization, and product launch by reflecting real-world decision-making processes and payer perspectives. PayerPro360 addresses the common challenges in payer research- ensuring efficient, real-time engagement with high data accuracy and cost efficiency- ultimately providing a simplified, flexible solution to access actionable insights.

## OBJECTIVE

Poor graft function (PGF) that may occur after allogeneic hematopoietic cell transplantation (HCT) does not respond well to current therapies. This research elucidates the areas of unmet need in managing PGF and the expected characteristics of an ideal treatment for PGF


## METHOD

An online survey was conducted through eQuantX's PayerPro360 platform, engaging 10+ private and institutional payers in the United States in 2022, with expertise in pricing, reimbursement, patient access, policy, and advocacy programs. The payer profiles included key institutions such as Boston Medical Center (BMC), New York Blood Center, National Comprehensive Care Network (NCCN), and the Center for International Blood & Marrow Transplant Research, alongside government payers like the U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS). Major private payers were also represented, including Cigna, Anthem, UnitedHealth Group, BlueCross BlueShield, Humana, and Aetna. Utilizing PayerPro360's interactive features, real-time insights were gathered over a week, allowing the research team to pinpoint unmet needs in HCT patients with poor graft function and identify the most widely used treatments within this patient population. PayerPro360's agile platform facilitated follow-up inquiries for in-depth clarification, highlighting the critical challenges these payers encounter in managing HCT patients with poor graft function.





## RESULTS

### Characteristics, risk factors, causes and management of PGF



### Patient Journey: PGF following HSCT



## CONCLUSIONS

The insights gathered from payers highlight significant challenges in the current management of poor graft function (PGF), affecting approximately 7% of patients post-HCT. Payers outlined the characteristics of an ideal treatment, which would accelerate recovery post-HCT, prevent GVHD, lower infection risks, reduce hospital readmissions, and improve survival rates for patients with primary cancers. Some payers also emphasized the need for a prophylactic treatment to prevent PGF occurrence.

Utilizing the PayerPro360 platform proved instrumental in gathering these insights, providing a dynamic interface for real-time payer engagement. By delivering accurate, actionable data on market access, pricing, and reimbursement requirements, PayerPro360 aids product development teams in refining target product profiles and aligning with payer expectations in these high-need therapeutic areas.

Payer-based primary market research for 10+ private and institutional payers in the United States

## CONTACT INFORMATION

email: [piyush@equantx.com](mailto:piyush@equantx.com), [c.senapati@equantx.com](mailto:c.senapati@equantx.com)  
+91 9981786703